MicroRNA-214 Regulates the Acquired Resistance to Gefitinib via the PTEN/AKT Pathway in EGFR-mutant Cell Lines |
Wang, Yong-Sheng
(Department of Oncology, Shanghai Pulmonary Hospital, Tongji University)
Wang, Yin-Hua (Department of Oncology, The Second People's Hospital of Wuhu City, Wannan Medical College) Xia, Hong-Ping (Department of Chemistry, University of Hong Kong) Zhou, Song-Wen (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University) Schmid-Bindert, Gerald (Department of Interdisciplinary Thoracic Oncology, University Medical Center Mannheim, Heidelberg University) Zhou, Cai-Cun (Department of Oncology, Shanghai Pulmonary Hospital, Tongji University) |
1 | Yang H, Kong W, He L, et al (2008). MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res, 68, 425-33. DOI |
2 | Yang Z, Chen S, Luan X, et al (2009). MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life, 61, 1075-82. DOI |
3 | Zhang XJ, Ye H, Zeng CW, et al (2010). Dysregulation of miR- 15a and miR-214 in human pancreatic cancer. J Hematol Oncol, 3, 46. |
4 | Zhou C, Wu YL, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol, 12, 735-42. DOI |
5 | Salomon DS, Brandt R, Ciardiello F, Normanno N (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hemat, 19, 183-232. DOI |
6 | Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32. DOI |
7 | Sos ML, Koker M, Weir BA, et al (2009). PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res, 69, 3256-61. DOI |
8 | Thatcher N, Chang A, Parikh P, et al (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366, 1527-37. DOI |
9 | Sulis ML, Parsons R (2003). PTEN: from pathology to biology. Trends Cell Biol 13, 478-83. DOI |
10 | Tamura M, Gu J, Matsumoto K, et al (1998). Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science, 280, 1614-7. DOI |
11 | Weiss GJ, Bemis LT, Nakajima E, et al (2008). EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol, 19, 1053-9. DOI |
12 | Xia L, Zhang D, Du R, et al (2008). miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer, 123, 372-9. DOI |
13 | Yamasaki F, Johansen MJ, Zhang D, et al (2007). Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and upregulation of phosphorylated Akt. Cancer Res, 67, 5779-88. DOI |
14 | Yanaihara N, Caplen N, Bowman E, et al (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9, 189-98. DOI |
15 | Kosaka T, Yatabe Y, Endoh H, et al (2006). Analysis of epidermal growth factor receptor gene mutation in patients with nonsmall cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res, 12, 5764-9. DOI |
16 | Lee KM, Choi EJ, Kim IA (2011). microRNA-7 increases radiosensitivity of human cancer cells with activated EGFRassociated signaling. Radiother Oncol, 101, 171-6. DOI |
17 | Mellinghoff IK, Cloughesy TF, Mischel PS (2007). PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res, 13, 378-81. DOI |
18 | Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8. DOI |
19 | Maemondo M, Inoue A, Kobayashi K, et al (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362, 2380-8. DOI |
20 | Magrelli A, Azzalin G, Salvatore M, et al (2009). Altered microRNA expression patterns in hepatoblastoma patients. Transl Oncol, 2, 157-63. DOI |
21 | Mendelsohn J, Baselga J (2000). The EGF receptor family as targets for cancer therapy. Oncogene, 19, 6550-65. DOI |
22 | Miller TE, Ghoshal K, Ramaswamy B, et al (2008). MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem, 283, 29897-903. DOI |
23 | Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57. DOI |
24 | Pao W, Miller VA, Politi KA, et al (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2, e73. |
25 | Pillai RS (2005). MicroRNA function: multiple mechanisms for a tiny RNA? RNA, 11, 1753-61. DOI |
26 | Derfoul, A, Juan AH, Difilippantonio MJ, et al (2011). Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis, 32, 1607-14. DOI |
27 | Fu YF, Du TT, Dong M, et al (2009). Mir-144 selectively regulates embryonic -hemoglobin synthesis during primitive erythropoiesis. Blood, 113, 1340-9. DOI |
28 | Engelman JA, Mukohara T, Zejnullahu K, et al (2006). Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest, 116, 2695-706. DOI |
29 | Engelman JA, Zejnullahu K, Mitsudomi T, et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039-43. DOI |
30 | Esquela-Kerscher A, Slack FJ (2006). Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer, 6, 259-69. DOI |
31 | Hanahan D and Weinberg RA (2000). The hallmarks of cancer. Cell, 100, 57-70. DOI |
32 | He L, Hannon GJ (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet, 5, 522-31. DOI |
33 | Hu SJ, Ren G, Liu JL, et al (2008). MicroRNA expression and regulation in mouse uterus during embryo implantation. J Biol Chem, 283, 23473-84. DOI |
34 | Hwang HW, Mendell JT (2006). MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer, 94, 776-80. DOI |
35 | Jackman D, Pao W, Riely GJ, et al (2010). Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol, 28, 357-60. DOI |
36 | Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. DOI |
37 | Blower PE, Chung JH, Verducci JS, et al. (2008). MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther, 7, 1-9. DOI |
38 | Bartel DP (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-33. DOI |
39 | Bean J, Brennan C, Shih JY, et al (2007). MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA, 104, 20932-7. DOI |